Evidence map›Paper›PMID 41561743›Full record

ArticleFrontiers in oncology2025

Case Report: A case of lymph node metastatic cancer of unknown primary with elevated alpha-fetoprotein achieving long-term survival.

Yan Wang, Chao-Qun Wang, Bi-Fei Huang

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yan WangDepartment of Medical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Chao-Qun WangDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Bi-Fei HuangDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Carcinoma of unknown primary (CUP) is typically associated with a poor prognosis, with a median survival of less than one year. This article reports a rare case of an alpha-fetoprotein (AFP)-positive CUP patient who achieved a long-term survival of nearly five years, whose diagnostic and therapeutic course offers significant clinical insights. Case presentation: A 67-year-old male patient presented with left neck lymphadenopathy. A comprehensive workup revealed no primary site, leading to a diagnosis of CUP. Although subsequent immunohistochemistry classified the case into the unfavorable prognostic subgroup, an individualized treatment strategy including three-drug combination chemotherapy based on the clinical suspicion of gastric cancer, targeted therapy with Apatinib, and localized radiotherapy, resulted in a remarkably long overall survival of 58 months. Serum AFP levels closely correlated with disease activity throughout the clinical course. Conclusions: This case demonstrates that for CUP confined to lymph nodes, active and precisely reasoned individualized treatment can significantly improve prognosis, even in cases categorized as having an unfavorable prognosis. Furthermore, it underscores the necessity of immunohistochemistry for the accurate diagnosis of CUP and suggests that promoting precision medicine strategies may improve outcomes for these patients.

Indexed as

alpha-fetoproteincarcinoma of unknown primarycase reportmetastasissurvival

Identifiers

PMID41561743
PMCPMC12812528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.